Clinical Pharmacology & Therapeutics · 2017 · 50 citations · 28 references
MedicineOncologyPharmacologyCancer PreventionClinical PharmacologyGastrointestinal OncologyCancer BiomarkersColorectal CancerOncology PharmacologyAspirin ChemopreventionColorectal Cancer ChemopreventionColorectal Cancer PreventionColorectal Carcinogenesis PathophysiologyCyclooxygenase Pathway SignalingCyclooxygenase-1 InhibitionGastrointestinal MucosaProstaglandin Pharmacology
The mechanism of action of low‐dose aspirin in the prevention of colorectal cancer (CRC) remains largely hypothetical. We aimed to compare the effects of low‐dose aspirin (100 mg/day for 7 days) given to 40 individuals undergoing CRC screening on the extent of cyclooxygenase (COX)‐1 acetylation at serine‐529 (AceCOX‐1), in blood platelets vs. colorectal mucosa, at 7 (group 1) and 24 h (group 2) after dosing. A significantly ( P < 0.01) lower %AceCOX‐1 was detected in colonic and rectal mucosa (average 64%) vs. platelets (average 75%) in both groups. This effect was associated with an average 46% ( P < 0.01) and 35% ( P < 0.05) reduction in prostaglandin (PG) E 2 levels and phosphorylated S6 (p‐S6) levels, respectively. Rectal mucosal levels of p‐S6/S6 significantly ( P < 0.01) correlated with PGE 2 . These findings demonstrate that low‐dose aspirin produces long‐lasting acetylation of COX‐1 and downregulation of p‐S6 in human colorectal mucosa, an effect that may interfere with early colorectal carcinogenesis.
28
Brendan McAdam, Francesca Catella-Lawson, Issam A. Mardini et al. · Proceedings of the National Academy of Sciences · 1999 · 1.3K citations
Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects
Carlo Patrono, Giovanni Ciabattoni, E Pinca et al. · Thrombosis Research · 1980 · 648 citations
Medicine, Hematology, Pharmacology +12